Michael G. Dunn

NovoPedics, Inc. develops implantable medical devices that restore mobility to patients suffering from severe meniscus knee injuries. It provides a way to replace damaged meniscus tissue with a patented fiber-reinforced design similar to the native meniscus and can be attached to both soft tissue and bone, allowing it to be used in total meniscus replacement surgery. The company was founded by Charles J. Gatt Jr. and Michael G. Dunn in 2013 and is headquartered in New Brunswick, NJ.

NovoPedics, Inc. develops implantable medical devices that restore mobility to patients suffering from severe meniscus knee injuries. It provides a way to replace damaged meniscus tissue with a patented fiber-reinforced design similar to the native meniscus and can be attached to both soft tissue and bone, allowing it to be used in total meniscus replacement surgery. The company was founded by Charles J. Gatt Jr. and Michael G. Dunn in 2013 and is headquartered in New Brunswick, NJ.

NovoPedics, Inc. develops implantable medical devices that restore mobility to patients suffering from severe meniscus knee injuries. It provides a way to replace damaged meniscus tissue with a patented fiber-reinforced design similar to the native meniscus and can be attached to both soft tissue and bone, allowing it to be used in total meniscus replacement surgery. The company was founded by Charles J. Gatt Jr. and Michael G. Dunn in 2013 and is headquartered in New Brunswick, NJ.